EURUSD Bid: --
USDJPY Bid: --
GBPUSD Bid: --
USDCHF Bid: --
AUDUSD Bid: --
USDCAD Bid: --
NZDUSD Bid: --
EURGBP Bid: --
GBPJPY Bid: --
WTI Bid: --
BRENT Bid: --
XAUUSD Bid: --
XAGUSD Bid: --
SPX500 Bid: --
DAX40 Bid: --
US30 Bid: --
JPN225 Bid: --
NAS100 Bid: --
UK100 Bid: --
BTCUSD Bid: --
ETHUSD Bid: --
LTCUSD Bid: --
XRPUSD Bid: --
EURUSD Bid: --
USDJPY Bid: --
GBPUSD Bid: --
USDCHF Bid: --
AUDUSD Bid: --
USDCAD Bid: --
NZDUSD Bid: --
EURGBP Bid: --
GBPJPY Bid: --
WTI Bid: --
BRENT Bid: --
XAUUSD Bid: --
XAGUSD Bid: --
SPX500 Bid: --
DAX40 Bid: --
US30 Bid: --
JPN225 Bid: --
NAS100 Bid: --
UK100 Bid: --
BTCUSD Bid: --
ETHUSD Bid: --
LTCUSD Bid: --
XRPUSD Bid: --

Dukascopy Operating Income Jumps 12% as FX Trading Gains Offset Commission Drop

Posted: 30th Apr 2026

Dukascopy Bank grew total operating income by around 12% in 2025 to CHF 20.8 million, up from CHF 18.5 million a year earlier, while net profit jumped to CHF 1.2 million from CHF 0.2 million as stronger trading and lower costs offset weaker commissions.

The improvement came despite a zero policy rate in Switzerland and a volatile geopolitical backdrop, with the Geneva‑based online bank using forex and CFD market swings to support activity.

Trading and Deposits Drive Recovery

Forex trading profitability rose 25.5% in 2025, underscoring the central role of trading income in Dukascopy’s model. Result from trading activities reached CHF 16.5 million compared with CHF 14.7 million in 2024, while net commission income fell to CHF 1.4 million from CHF 3.2 million as commission expenses increased.

Client money continued to grow. Total client deposits climbed 15.6% over the year to CHF 188.6 million, from CHF 163.1 million at the end of 2024, helping lift total assets to CHF 256.5 million from CHF 235.1 million. Multi‑currency accounts expanded further, with balances on MCA accounts rising 34.1% from CHF 102.5 million to CHF 137.5 million and generating CHF 4.9 million in gross revenue.

The bank also broadened its product set. It added more than 300 cross instruments during 2025 and pushed FX swap turnover since February 2024 above CHF 1.9 billion. The number of processed payments increased by 24% year on year, reflecting rising use by both retail and corporate clients.

Costs, Crypto and Outlook

Dukascopy tightened costs alongside revenue growth. Operating expenses fell 5% to CHF 18.8 million in 2025 from CHF 19.8 million in 2024, bringing the cost‑income ratio down to 90.2% from 107.4%, though still above the 89.2% level in 2023. Personnel expenses declined and general and administrative costs edged lower as the bank used technology to scale operations.

Crypto‑related activity remained a strategic focus. More than 8.1 million Dukascoins were outstanding by year‑end and the bank continued to develop crypto‑fiat functionality within its regulated framework. Management reports a good start to 2026 but flags higher geopolitical risk and leans on new products in trading, payments and crypto to counter tougher markets.

Dukascopy Sharpens Crypto Accounting

Dukascopy’s 2025 report sets out a clear framework for how it treats crypto assets, including its own token, Dukascoin. Crypto that the bank holds for investment sits under “financial investments” and is measured at acquisition cost, then at the lower of cost or market, while crypto that it holds for trading appears in “trading assets” at fair value, with gains and losses recorded in “result from trading activities.”

Recently, Dukascopy expanded its MT5 lineup from just over 100 to more than 400 instruments, adding gold, silver, a wider range of FX crosses and new crypto CFDsIt is a part of the firm's expansion of its broader multi‑platform offering alongside MT4 and JForex and follows last year’s addition of 303 new instruments on JForex.

The expansion came after a sharp improvement in financial performance in H1 2025, when standalone profit jumped to CHF 3.32 million from CHF 19.8 thousand and consolidated profit rose to CHF 3.29 million from CHF 80.8 thousand.

This article was written by Jared Kirui at www.financemagnates.com.

Source: Finance Magnates

Follow us on
Website Managed by BuiltByGo
Disclaimer: The information provided on FX Axe is for educational and informational purposes only and should not be construed as financial advice. Trading Foreign Exchange (FX), Contracts for Difference (CFDs), and other leveraged financial products involves a high level of risk and may not be suitable for all investors. Leverage can work both to your advantage and disadvantage, and as a result, you may lose more than your initial investment. Before deciding to trade FX, CFDs, or any other financial instrument, you should carefully consider your investment objectives, level of experience, and risk tolerance. You should not invest money that you cannot afford to lose. It is strongly advised that you seek independent financial advice if you have any doubts. FX Axe does not provide investment, tax, legal, or financial advice of any kind. We may receive compensation from brokers and partners featured on this website, but such relationships do not influence our reviews or recommendations. All reviews are based on our own opinions and research and should not be interpreted as endorsements or guarantees of any service. Past performance is not indicative of future results. The trading of FX and CFDs carries a significant risk of loss. By using this website, you acknowledge that FX Axe bears no responsibility for any losses you may incur from your trading activities or reliance on information provided here.

Affiliate Disclosure: Some of the links and references on FX Axe may relate to third-party brokers or service providers. In certain cases, we may receive compensation if you choose to engage with these providers through our website. This helps support the ongoing operation of the site and allows us to continue publishing content at no direct cost to our readers. Our content is created with the aim of being informative and useful. While commercial relationships may exist, we strive to ensure that the information presented remains objective and based on our own research and perspective.
cross